Jennifer S. Lawton

Johns Hopkins University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Background Limited data exist on sex differences in guideline‐recommended statin therapy for secondary prevention after coronary artery bypass surgery (CABG). We examined sex differences in statin use after CABG and the association between sex‐specific statin use and mortality. Methods and Results Data from the Austrian national cardiac surgery registry and federal social insurance claims database for patients who underwent CABG between 2013 and 2021 were used. Multivariable logistic regression models were calculated to obtain women‐to‐men odds ratios for filling any statin and high‐intensity statin prescriptions. Cox proportional hazards models were used to evaluate the association between statin use and mortality. A total of 15 448 patients (19% women) were included. During the 5 years after CABG, statin use decreased from 95.7% to 85.9% in men and 95.2% to 84.3% in women (P for trend <0.0001; P int =0.48), high‐intensity statin use decreased from 69.4% to 57.2% in men and 67.8% to 54.3% in women (P for trend <0.0001; P int =0.59). The adjusted odds ratio for filling any statin prescription comparing women with men was 1.03 (95% CI, 0.92–1.16) and for filling a high‐intensity statin prescription was 1.12 (95% CI, 1.02–1.23). Statin use was associated with a significantly lower mortality risk in both sexes (any statin: hazard ratio [HR], 0.56 [95% CI, 0.46–0.68]; P <0.0001, P int =0.22; high‐intensity statin: HR, 0.52 [95% CI, 0.42–0.63]; P <0.0001, P int =0.48). Conclusions Women were as likely as men to fill a statin prescription after CABG and more likely to fill a high‐intensity prescription. Statin use was associated with a similar mortality risk reduction among women and men.

Year:

2025

Objectives: Risk assessment models for cardiac surgery do not distinguish between degrees of liver dysfunction. We have previously shown that preoperative liver stiffness is associated with hospital length of stay following cardiac surgery. The authors hypothesized that a liver stiffness measurement (LSM) ≥ 9.5 kPa would rule out a short hospital length of stay (LOS < 6 days) following isolated coronary artery bypass grafting (CABG) surgery. Methods: A prospective observational study of one hundred sixty-four adult patients undergoing non-emergent isolated CABG surgery at a single university hospital center. Preoperative liver stiffness measured by ultrasound elastography was obtained for each participant. Multivariate logistic regression models were used to assess the adjusted relationship between LSM and a short hospital stay. Results: We performed multivariate logistic regression models using short hospital LOS (<6 days) as the dependent variable. Independent variables included LSM (< 9.5 kPa, ≥ 9.5 kPa), age, sex, STS predicted morbidity and mortality, and baseline hemoglobin. After adjusting for included variables, LSM ≥ 9.5 kPa was associated with lower odds of early discharge as compared to LSM < 9.5 kPa (OR: 0.22, 95% CI: 0.06–0.84, p = 0.03). The ROC curve and resulting AUC of 0.76 (95% CI: 0.68–0.83) suggest the final multivariate model provides good discriminatory performance when predicting early discharge. Conclusions: A preoperative LSM ≥ 9.5 kPa ruled out a short length of stay in nearly 80% of patients when compared to patients with a LSM < 9.5 kPa. Preoperative liver stiffness may be a useful metric to incorporate into preoperative risk stratification.

Year:

2024

Background ATP‐sensitive potassium channels are inhibited by ATP and open during metabolic stress, providing endogenous myocardial protection. Pharmacologic opening of ATP potassium channels with diazoxide preserves myocardial function following prolonged global ischemia, making it an ideal candidate for use during cardiac surgery. We hypothesized that diazoxide would reduce myocardial stunning after regional ischemia with subsequent prolonged global ischemia, similar to the clinical situation of myocardial ischemia at the time of revascularization. Methods and Results Swine underwent left anterior descending occlusion (30 minutes), followed by 120 minutes global ischemia protected with hyperkalemic cardioplegia±diazoxide (N=6 each), every 20 minutes cardioplegia, then 60 minutes reperfusion. Cardiac output, time to wean from cardiopulmonary bypass, left ventricular (LV) function, caspase‐3, and infarct size were compared. Six animals in the diazoxide group separated from bypass by 30 minutes, whereas only 4 animals in the cardioplegia group separated. Diazoxide was associated with shorter but not significant time to wean from bypass (17.5 versus 27.0 minutes; P =0.13), higher, but not significant, cardiac output during reperfusion (2.9 versus 1.5 L/min at 30 minutes; P =0.05), and significantly higher left ventricular ejection fraction at 30 minutes (42.5 versus 15.8%; P <0.01). Linear mixed regression modeling demonstrated greater left ventricular developed pressure ( P <0.01) and maximum change in ventricular pressure during isovolumetric contraction ( P <0.01) in the diazoxide group at 30 minutes of reperfusion. Conclusions Diazoxide reduces myocardial stunning and facilitates separation from cardiopulmonary bypass in a model that mimics the clinical setting of ongoing myocardial ischemia before revascularization. Diazoxide has the potential to reduce myocardial stunning in the clinical setting.

Year:

2022

Collaborators (4)

Sigrid Sandner

Medical University of Vienna

AUSTRIA
View details

Ahmet Kilic

-

UNITED STATES
View details

Monika M. Safford

Weill Cornell Medicine

UNITED STATES
View details

Andreas Zuckermann

Director Cardiac transplantation

Medical University of Vienna

AUSTRIA
View details